OncoMatch/Clinical Trials/NCT06289062

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Is NCT06289062 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Cisplatin for cervical cancer.

Phase 2RecruitingTongji HospitalNCT06289062Data as of May 2026

Treatment: Camrelizumab · Cisplatin · Nab paclitaxel — This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Biomarker criteria

Required: PD-L1 (CD274) overexpression (CPS ≥1)

Positive PD-L1 expression by preoperative pathology, i.e., Combined Positive Score (CPS) ≥1

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immune checkpoint inhibitor

Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies

Cannot have received: chemotherapy

receipt of chemotherapy

Cannot have received: radiation therapy

receipt of...pelvic radiation

Cannot have received: allogeneic bone marrow or solid organ transplant

Patients who have received a previous allogeneic bone marrow or solid organ transplant

Lab requirements

Blood counts

white blood cell (wbc) ≥3.5×10^9/l, neutrophil (neu) ≥1.5×10^9/l, platelet (plt) ≥100×10^9/l

Kidney function

blood urea nitrogen (bun) and cr ≤normal

Liver function

serum bilirubin ≤1.5 times the upper limit of normal, aminotransferase ≤1.5 times the upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify